Ocular Therapeutix, Inc. (NASDAQ:OCUL) Holdings Raised by Rosalind Advisors Inc.

Rosalind Advisors Inc. lifted its stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL) by 27.5% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,128,700 shares of the biopharmaceutical company’s stock after purchasing an additional 243,700 shares during the quarter. Ocular Therapeutix comprises about 4.8% of Rosalind Advisors Inc.’s portfolio, making the stock its 7th largest holding. Rosalind Advisors Inc. owned about 0.72% of Ocular Therapeutix worth $9,639,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. Charles Schwab Investment Management Inc. raised its holdings in shares of Ocular Therapeutix by 146.6% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,110,460 shares of the biopharmaceutical company’s stock worth $9,661,000 after buying an additional 660,080 shares during the last quarter. Patient Square Capital LP acquired a new position in shares of Ocular Therapeutix in the 3rd quarter valued at $2,049,000. Polar Asset Management Partners Inc. purchased a new position in Ocular Therapeutix in the 3rd quarter worth $4,288,000. FMR LLC lifted its position in Ocular Therapeutix by 7,098.7% during the 3rd quarter. FMR LLC now owns 434,369 shares of the biopharmaceutical company’s stock worth $3,779,000 after acquiring an additional 428,335 shares during the period. Finally, Knoll Capital Management LLC grew its stake in Ocular Therapeutix by 199.6% during the 3rd quarter. Knoll Capital Management LLC now owns 600,400 shares of the biopharmaceutical company’s stock valued at $5,223,000 after purchasing an additional 400,000 shares during the last quarter. 59.21% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Ocular Therapeutix

In related news, insider Donald Notman sold 6,301 shares of the company’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $7.84, for a total transaction of $49,399.84. Following the completion of the sale, the insider now owns 204,563 shares of the company’s stock, valued at approximately $1,603,773.92. This represents a 2.99 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Pravin Dugel sold 21,475 shares of the stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $6.87, for a total value of $147,533.25. Following the completion of the sale, the insider now directly owns 3,520,318 shares of the company’s stock, valued at approximately $24,184,584.66. This represents a 0.61 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 38,895 shares of company stock valued at $283,772. 3.50% of the stock is owned by corporate insiders.

Ocular Therapeutix Stock Performance

Shares of NASDAQ OCUL opened at $7.51 on Friday. Ocular Therapeutix, Inc. has a 1 year low of $4.06 and a 1 year high of $11.78. The company has a debt-to-equity ratio of 0.19, a quick ratio of 12.94 and a current ratio of 13.01. The company’s fifty day moving average price is $7.57 and its 200 day moving average price is $8.78. The company has a market capitalization of $1.19 billion, a PE ratio of -5.69 and a beta of 1.34.

Ocular Therapeutix (NASDAQ:OCUL) last announced its earnings results on Monday, March 3rd. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.05). The business had revenue of $17.08 million for the quarter, compared to analyst estimates of $16.89 million. Ocular Therapeutix had a negative return on equity of 45.18% and a negative net margin of 283.74%. On average, research analysts predict that Ocular Therapeutix, Inc. will post -0.98 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the company. JMP Securities set a $19.00 price objective on Ocular Therapeutix in a research note on Tuesday, March 4th. Royal Bank of Canada initiated coverage on shares of Ocular Therapeutix in a research report on Tuesday. They set an “outperform” rating and a $17.00 price target for the company. Needham & Company LLC began coverage on shares of Ocular Therapeutix in a report on Tuesday, March 11th. They issued a “buy” rating and a $15.00 price objective on the stock. Finally, HC Wainwright reissued a “buy” rating and set a $15.00 target price on shares of Ocular Therapeutix in a report on Tuesday, March 4th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, Ocular Therapeutix has a consensus rating of “Moderate Buy” and an average target price of $16.38.

About Ocular Therapeutix

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.